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ABSTRACT
Objective To investigate the role of inﬂammation in the
phenotypic expression of myocardial ﬁbrosis in
hypertrophic cardiomyopathy (HCM).
Design Clinical study.
Setting Kuopio University Hospital and University of
Eastern Finland, Kuopio, Finland.
Subjects Twenty-four patients with a single HCM-
causing mutation D175N in the a-tropomyosin gene and
17 control subjects.
Main outcome measures Endomyocardial biopsy
samples taken from the patients with HCM were
compared with matched myocardial autopsy specimens.
Levels of high-sensitivity C-reactive protein (hsCRP) and
proinﬂammatory cytokines were measured in patients
and controls. Myocardial late gadolinium enhancement
(LGE) in cardiac MRI (CMRI) was detected.
Results Endomyocardial samples in patients with HCM
showed variable myocyte hypertrophy and size
heterogeneity, myoﬁbre disarray, ﬁbrosis, inﬂammatory
cell inﬁltration and nuclear factor kappa B (NF-kB)
activation. Levels of hsCRP and interleukins (IL-1b,
IL-1RA, IL-6, IL-10) were signiﬁcantly higher in patients
with HCM than in control subjects. In patients with HCM,
there was a signiﬁcant association between the degree
of myocardial inﬂammatory cell inﬁltration, ﬁbrosis in
histopathological samples and myocardial LGE in CMRI.
Levels of hsCRP were signiﬁcantly associated with
histopathological myocardial ﬁbrosis. hsCRP, tumour
necrosis factor a and IL-1RA levels had signiﬁcant
correlations with LGE in CMRI.
Conclusions A variable myocardial and systemic
inﬂammatory response was demonstrated in patients
with HCM attributable to an identiﬁed sarcometric
mutation. Inﬂammatory response was associated with
myocardial ﬁbrosis, suggesting that myocardial ﬁbrosis in
HCM is an active process modiﬁed by an inﬂammatory
response.
INTRODUCTION
Hypertrophic cardiomyopathy (HCM), most
commonly caused by mutations in sarcomeric
genes, is a myocardial disease characterised by left
ventricular hypertrophy, myocyte disarray and
myocardial ﬁbrosis.
1 The cardiac phenotype in
HCM varies between unrelated individuals and also
between family members with an identical disease-
causing sarcomeric mutation, suggesting that HCM
is a complex inherited disease modiﬁed by other
genetic and environmental factors.
1e5 The molec-
ular events triggered by the genotype or other
factors that induce the cardiac phenotype, partic-
ularly ﬁbrosis, remain to be determined.
4e6
Previous studies have shown that chronic
inﬂammation decreases myocardial contractility,
induces hypertrophy and promotes apoptosis and
ﬁbrosis, thus contributing to myocardial remod-
elling.
7e9 Inﬂammatory cytokines, tumour necrosis
factor a (TNFa), interleukin (IL)-1 and IL-6, are not
constitutively expressed in the normal heart, but
are upregulated and produced as a stress response to
myocardial injury or mechanical stress.
8 TNFa and
IL-6 can directly attenuate myocardial contractility
and induce the development of myocyte hyper-
trophy, collagen deposition and ﬁbrosis.
8 IL-1b has
been correlated with myocardial collagen deposi-
tion, cardiomyocyte apoptosis and inﬂammation.
10
The expression of both inﬂammatory and anti-
inﬂammatory cytokines is increased in heart
failure.
9 In addition, nuclear factor k B (NF-kB),
a transcription factor regulating inﬂammatory
genes, has been shown to be activated in patients
with heart failure of various causes.
11
Circulating inﬂammatory cytokines are raised in
HCM,
12e14 but none of the previous studies has
investigated the association of cytokine levels with
cardiac phenotype determined by cardiac MRI
(CMRI). Furthermore, there are no previous studies
on NF-kB activation in HCM. Even more impor-
tantly, there are few data on myocardial histo-
pathological ﬁndings or inﬂammatory response in
patients with HCM caused by a speciﬁc sarcomeric
gene mutation. Therefore, to investigate the role of
inﬂammation in the phenotypic expression of
myocardial ﬁbrosis in HCM, we investigated
cardiac histopathology, inﬂammatory cytokine and
high-sensitivity C-reactive protein (hsCRP) levels
and cardiac phenotype by CMRI in patients with
HCM attributable to an identical HCM-causing
mutation D175N in the a-tropomyosin gene
(TPM1-D175N).
PATIENTS AND METHODS
The study protocol was approved by the ethics
committee of the Kuopio University Hospital. All
subjects gave written informed consent. Consent
to the use of cadaver myocardial samples was
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Hypertrophic cardiomyopathyobtained from the Finnish Center for Legal Proctection in Health
Care. Data of endomyocardial biopsy and cytokine ﬁndings have
not been published in any form. Previously, we have published
studies on CMRI-derived myocardial perfusion, myocardial late
gadolinium enhancement (LGE), myocardial contractile impair-
ment and inducibility of life-threatening arrhythmias in this
same patient population.
2 15e17
Patients with HCM
Twenty-four patients from ﬁve Finnish families (11 men,
13 women; mean age, 42613 years; age range, 17e68 years) with
HCM attributable to the mutation D175N in the a-tropomyosin
gene (TPM1-D175N)
18 19 were included in the study. In Finland,
TPM1-D175N is one of the two founder mutations causing about
11% of all, and 25% of familial, HCM cases in eastern Finland.
19
Of 24 subjects with TPM1-D175N, two did not meet the diag-
nostic criteria for clinical HCM and were regarded as healthy
mutation carriers. All subjects with TPM1-D175N, however, are
called ‘patients with HCM’ in the subsequent analysis. The study
protocol described below was performed during one 2-day visit to
the Kuopio University Hospital.
Control subjects
Seventeen healthy volunteers not related to patients with HCM
and without a previous cardiac disease or drug treatment and
with race, gender and age similar to the patients with HCM,
were included into our study. Study protocol was identical to
that for the patients with HCM, except for cardiac catheter-
isation and endomyocardial biopsy.
For histopathological analyses, control myocardial specimens
were obtained from 20 cadavers matched for age, gender and race
without known cardiac disease (no history of a cardiac disease,
normal macroscopic myocardial ﬁndings and no clear evidence of
a speciﬁc myocardial disease on microscopic examination).
Clinical and echocardiographic evaluation
All patients with HCM and control subjects underwent an
interview, physical examination, 12-lead ECG recording and
echocardiography, as previously described.
2 15e17
CMRI protocol
CMRI cine, perfusion and LGE imaging were performed in
patients with HCM and controls as previously described.
2 15 16
CMRI cine imaging was performed in all patients, perfusion
imaging in 17 patients with HCM and LGE imaging in
22 patients with HCM.
CMRI image analysis
Left ventricular (LV) characteristics and myocardial perfusion by
CMRI were evaluated. LGE image analysis was performed in LV
short-axis images at the levels of tips of the mitral valve leaﬂets
and papillary muscles.
16 In statistical analyses, the maximal
value of the six segmental LGE heterogeneity values was used.
Figure 1 shows LGE images of one control subject and three
patients with HCM.
Coronary angiography
Coronary angiography was performed on 21 of 24 patients with
HCM using standard angiographic techniques by the same
cardiologist (JK).
Endomyocardial biopsy and autopsy myocardial samples
Myocardial specimens for histological analysis and immunohis-
tochemistry were obtained from 20 patients with HCM.
Endomyocardial biopsy samples were obtained under ﬂuoro-
scopic guidance from the right ventricle side of the interven-
tricular septum with the standard endomyocardial bioptome.
Control cadaver samples were selected from the archives of the
department of clinical pathology of Kuopio University Hospital.
Representative myocardial routine autopsy specimens from the
anterior, posterior or septal wall of the heart were taken from
20 matched cadavers.
Histological and immunohistochemical methods
Histological methods and immunochemistry analyses are
described in detail in the online supplementary information.
Laboratory determinations of cytokines and hsCRP
Plasma concentrations of TNFa, IL-6, IL-10, IL-1b and IL-1RA
were measured using assay kits from R&D Systems (Minneap-
olis, USA). hsCRP was measured using an Immulite analyser and
a DPC hsCRP assay (DPC, Los Angeles, California, USA) in all
24 patients with HCM and in 17 controls.
Statistical analysis
Data are given as mean6SD. Statistical analyses were performed
with a statistical software package (SPSS Win V.11.5., SPSS Inc).
Because of skewed distribution, LV mass and all cytokines were
analysed after logarithmic transformation. The differences
between the patients and controls were assessed by Student t test.
ManneWhitney test was used to investigate the association
between endomyocardial ﬁndings and proinﬂammatory cyto-
kines. Pearson’s correlation coefﬁcients were calculated to inves-
tigate the association of cytokines with LGE in CMRI.
Spearman’s correlation coefﬁcient was used to investigate the
association of different histopathological features, the association
between histopathological inﬂammation and ﬁbrosis and between
histopathological inﬂammation/ﬁbrosis and LGE in CMRI.
Figure 1 Contrast-enhanced T1-weighted inversion recovery images in
(A) a 52-year-old control subject; (B) a 45-year-old male patient with
hypertrophic cardiomyopathy (HCM); (C) a 37-year-old female patient
with HCM; (D) 19-year-old male patient with HCM. Patients with HCM
(BeD) show intramyocardial focal high signal areas (arrows) with
increased segmental late gadolinium enhancement.
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Hypertrophic cardiomyopathyRESULTS
Clinical, echocardiographic and CMRI characteristics
Clinical, echocardiographic and CMRI characteristics of the
patients with HCM and controls have been published previ-
ously
2 15e17 and are summarised in table 1. Patients with HCM
had stable mild to moderate symptoms (90% of patients had
New York Heart Association functional class IeII). None of the
subjects with HCM had a history or clinical symptoms or signs
of decompensated heart failure, myocarditis, systemic infection,
chronic inﬂammatory disease or life-threatening arrhythmias.
None of the patients had an intracardiac deﬁbrillator. About one-
third of the patients used cardiac medication, mostly b-blocking
agents. None of the patients was taking ACE inhibitors or AT1
receptor antagonists or medication for heart failure.
None of the subjects with HCM had a signiﬁcant LVoutﬂow
tract obstruction (>30 mm Hg) at rest. In CMRI, LV maximal
wall thickness was increased in patients with HCM compared
with controls. No difference was seen in global LV ejection
fraction between patients with HCM and control subjects, but
the number of hypokinetic segments was increased in patients
with HCM compared with controls.
2 The LV perfusion reserve
was lower and the maximal LV LGE increased in patients with
HCM compared with controls.
15 16
Coronary angiography in patients with HCM
Patients with HCM had normal coronary arteries except for one
patient with HCM, who had <50% stenosis in the left anterior
descending coronary artery and another patient who had <50%
stenosis in the left anterior descending, intermediate and right
coronary arteries.
Histological ﬁndings in endomyocardial samples
Table 2 shows the histopathological ﬁndings in haematox-
ylineeosin stained endomyocardial samples in patients with
HCM. Sufﬁcient endomyocardial biopsy samples for histology
were available for 16 of 20 patients with HCM. Histological
samples showed variable amounts of heterogeneity of myocyte
size, myocyte hypertrophy, myoﬁbre disarray, myocardial
ﬁbrosis, inﬂammatory cell inﬁltration and intramyocardial small
artery narrowing. Interstitial and perivascular ﬁbrosis was found
in about 90% of cases. Inﬂammatory cell inﬁltration, including
mainly mononuclear inﬂammatory cells and eosinophilic gran-
ulocytes, was found in 37% of the patients. Narrowed intra-
myocardial small arteries were found in one-quarter of the
patients. Figure 2 AeC shows typical, mild and marked histo-
pathological ﬁndings in patients with HCM, respectively.
In control cadaver myocardial samples, mild heterogeneity of
myocyte size was found in one of 20 specimens, mild myocyte
hypertrophy in seven samples, mild myoﬁbre disarray in one
sample, mild interstitial ﬁbrosis in ﬁve samples, mild inﬂam-
matory cell inﬁltration of mononuclear cells in one sample and
eosinophilic granulocytes and intramyocardial small artery
narrowing in none of the samples.
Immunohistochemical ﬁndings in endomyocardial samples
Immunostaining with rabbit anti-human antibody showed that
seven of 11 (64%) patient endomyocardial biopsy samples had
CD3 positivity implicating T-lymphocytes (two with moderate
and ﬁve with weak positive staining). We could, however,
replicate the CD3 positivity with NCL-CD3-PS1 in only one
patient endomyocardial biopsy sample showing marked
inﬂammatory response (ﬁgure 2C). In 20 control cadaver
myocardial samples, weak CD3 positivity with rabbit anti-
human antibody was found in two samples and CD3 positivity
with NCL-CD3-PS1 in none of the samples. B-lymphocytes
with M755 staining were not found in patients or controls.
Occasional macrophages with MO814 were found in one
patient sample only.
Picrosirius collagen staining was positive in 12 of 15 HCM
samples. Extensive ﬁbrosis was found in two cases (ﬁgure 3),
moderate ﬁbrosis in four cases and mild ﬁbrosis in six cases. In
Table 1 Clinical, echocardiographic and CMRI characteristics in
control subjects and patients with hypertrophic cardiomyopathy
Characteristics
Control subjects
(n[17)
Patients with HCM
(n[24)
Men/women 8/9 11/13
Age, years 38612 42613
Vmax, m/s 1.360.2 1.460.5
LV MRI ﬁndings
Maximal wall thickness, mm 9.761.7 19.564.9**
Mass, g 123632 151657
End-diastolic volume, ml 146625 122645**
End-systolic volume, ml 56615 52629
Hypokinetic segments, % 12612 37620**
Ejection fraction, % 61675 8 67
Perfusion reserve 1.8060.58 1.1260.35*
The heterogeneity of
late-enhancement, %
12631 8 611*
Vmax indicates maximum velocity in the Doppler signal from the jet in left ventricular outﬂow
tract.
Data are means6SD.
*p<0.05, **p<0.001.
CMRI, cardiac magnetic resonance imaging; HCM, hypertrophic cardiomyopathy; LV, left
ventricular.
Table 2 Endomyocardial biopsy ﬁndings in 16/20 patients with
hypertrophic cardiomyopathy (haematoxylin-eosin staining)
Biopsy ﬁndings Number (%)
Heterogeneity in myocyte size
No 3 (19)
Moderate 6 (38)
Marked 7 (44)
Myocyte hypertrophy
No 1 (6)
Mild 11 (69)
Moderate 4 (25)
Myoﬁbre disarray
No 2 (13)
Mild 6 (38)
Moderate 6 (38)
Marked 2 (13)
Myocardial ﬁbrosis
No 2 (13)
Mild 6 (38)
Moderate 6 (38)
Marked 2 (13)
Inﬂammatory cell inﬁltration*
No 10 (63)
Mild 4 (25)
Moderate 1 (6)
Marked 1 (6)
Intramyocardial small artery narrowing
No 12 (75)
Mild 2 (13)
Moderate 1 (6)
Marked 1 (6)
*Eosinophilic granulocytes and mononuclear inﬂammatory cells.
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Hypertrophic cardiomyopathy20 control cadavers, mild ﬁbrosis in Picrosirius staining was
found in two cases.
NF-kB nuclear positivity was detected in eight of 15 patient
endomyocardial biopsy samples. NF-kB nuclear activity was
found in cardiomyocytes in four cases (three cases showed
NF-kB positivity in 20e50% of nuclei, one case in 5% of nuclei)
(ﬁgure 4). In three other cases, nuclear positivity of NF-kB was
found in inﬂammatory cells. Endothelial NF-kB nuclear posi-
tivity was found in one case. In control cadaver myocardial
specimens, no nuclear NF-kB positivity was detected.
Cytokines
Levels of hsCRP, IL-1b, IL-1RA, IL-6 and IL-10 were signiﬁcantly
higher in patients with HCM than in control subjects (table 3).
There was a trend towards higher TNFa levels in patients with
HCM compared with control subjects (p¼NS).
Associations between histopathological myocardial ﬁbrosis, LGE
and inﬂammatory response
In patients with HCM, the degree of histopathological
myocardial ﬁbrosis signiﬁcantly correlated with LGE in CMRI
(r¼0.568, p¼0.034). The grade of myocardial inﬂammatory cell
inﬁltration correlated with ﬁbrosis in histopathological samples
(r¼0.614, p¼0.011) and with LGE in CMRI (r¼0.541, p¼0.046).
Levels of hsCRP were signiﬁcantly associated with histo-
pathological myocardial ﬁbrosis (p<0.05). All other cytokine
levels tended to be higher in patients with moderate or marked
histopathological ﬁndings compared with those with no or
mild ﬁndings (p¼NS, data not shown). Cytokine levels did not
correlate signiﬁcantly with NF-kB activation (data not
shown).
Levels of hsCRP, TNFa and IL-1RA signiﬁcantly correlated
with maximal LGE in patients with HCM (table 4). There were
no signiﬁcant associations with IL-1b, IL-6, IL-10 and CMRI-
derived maximal LGE. There were no signiﬁcant associations of
cytokine levels with CMRI-derived maximal LV thickness,
LV mass, LV diastolic or systolic volumes, global ejection frac-
tion, or myocardial perfusion (data not shown).
DISCUSSION
Our study demonstrates that a low-grade myocardial and
general inﬂammatory response is present in HCM attributable
to a single well-documented causative sarcomeric mutation
(TPM1-D175N). Variable low-grade myocardial inﬂammation in
the patients with HCM was indicated by the presence of
myocardial inﬂammatory cell inﬁltration and enhanced nuclear
NF-kB activity in the myocardium and by increased levels of
hsCRP and circulating inﬂammatory cytokines. Myocardial
inﬂammatory cell inﬁltration and levels of hsCRP signiﬁcantly
correlated with histopathological myocardial ﬁbrosis and LGE in
CMRI and TNFa and IL-1RA correlated with LGE, suggesting
that myocardial ﬁbrosis in HCM may be an active process
modiﬁed by an inﬂammatory response.
Figure 2 (A) Typical histopathology in an endomyocardial biopsy of
a patient with hypertrophic cardiomyopathy (HCM). (a) A general view,
haematoxylin and eosin (H&E) 3200; (b, c) moderate ﬁbre disarray,
interstitial ﬁbrosis (asterisk), moderate myocyte size heterogeneity and
hypertrophy and scattered mononuclear inﬂammatory cells (arrows),
H&E 3400, 3630. (B) Mild histopathological ﬁndings in a patient with
HCM. (a) A general view, H&E 3200; (b, c) mild ﬁbre disarray, ﬁbrosis
(asterisk), myocyte hypertrophy and occasional mononuclear inﬂam-
matory cells (arrow), H&E 3400, 3630. (C) Severe HCM. (a) A general
view: Weigert van Gieson staining highlights marked ﬁbrosis (red,
shown by asterisk), 3200; (b) multiple mononuclear inﬂammatory cells
(arrow); (C) showing CD3 positivity in immunohistochemistry (staining in
brown, arrow). Original magniﬁcation 3400. The patient had severe
symptoms, marked left ventricular hypertrophy and inducible ventricular
arrhythmia in ventricular stimulation. An intracardiac deﬁbrillator was
subsequently implanted.
[Continued]
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Hypertrophic cardiomyopathyPotential pathogenic mechanism for myocardial ﬁbrosis
formation in HCM
Based on our ﬁndings we suggest a pathogenic mechanism for
myocardial ﬁbrosis formation in HCM. We propose that
myocardial ﬁbrosis in HCM is likely to be an active process, in
which primary injurydfor example, mechanical stress,
20 due to
disorganised sarcomeric and cellular architecture,
21 myocardial
ischaemia
22 or neuroendocrinological activation,
7 induces NF-kB
upregulation in the myocardium. NF-kB, in turn, activates
production of proinﬂammatory cytokines, inﬂammatory cell
invasion into the myocardium and activation of ﬁbroblasts,
ﬁnally leading to myocardial ﬁbrosis.
781 1
Histopathological myocardial phenotype and the causative
mutation in HCM
Endomyocardial samples in our patients with HCM showed
variable amounts of myocyte hypertrophy, myocyte size
heterogeneity, myoﬁbre disarray, myocardial ﬁbrosis, low-grade
inﬂammatory cell inﬁltration and intramyocardial small artery
narrowing. Transgenic mice carrying a single missense mutation
in codon 403 of the myosin heavy-chain gene exhibit variable
amounts of histopathological hypertrophy, myocyte disarray,
ﬁbrosis and susceptibility to induced arrhythmias.
23 In humans,
only limited information on histopathological myocardial ﬁnd-
ings in patients with HCM attributable to an identiﬁed sarco-
meric mutation has been published.
24 As histopathology appears
to vary to a great extent in humans and in transgenic animals
with identical disease-causing mutations, other factors than the
causative mutation necessarily contribute to histopathology in
HCM.
Chronic myocardial inﬂammatory cell inﬁltration in HCM
Mild to marked interstitial and perivascular inﬂammatory cell
inﬁltration of mononuclear inﬂammatory cells, showing CD3
positivity in immunostaining with rabbit anti-human antibody,
and of eosinophilic granulocytes, was found in over one-third of
histological endomyocardial specimens of the patients with
HCM. In one patient with severe HCM, inﬂammatory cell
inﬁltration was extensive (ﬁgure 2C). In contrast, practically no
inﬂammatory cells were recognised in control myocardial
samples. Three previous studies have reported that there is mild
chronic inﬂammatory cell inﬁltration in the myocardium of
patients with HCM,
3 25 26 but none of them has included
genotyped subjects.
Myocardial NF-kB activity in HCM
A new ﬁnding in our study was that immunohistochemical
staining for nuclear NF-kB activity was positive in half of the
endomyocardial samples of patients with HCM. NF-kB activa-
tion was detected particularly in cardiomyocytes, but also in
inﬂammatory and endothelial cells. None of the control
Figure 3 Endomyocardial ﬁbrosis in hypertrophic cardiomyopathy.
Increased ﬁbrosis is shown by Picrosirius Red staining (in red, asterisk).
Cardiomyocytes are pale yellow stained. Original magniﬁcation 3400.
Figure 4 Nuclear NF- kB activation is detected in cardiomyocytes
(arrows) in hypertrophic cardiomyopathy. 3400.
Table 3 Circulating levels of cytokines in control subjects and in
patients with hypertrophic cardiomyopathy
Cytokines
Control subjects (n[17) Patients with HCM (n[24)
Mean±SD Range Mean±SD Range
hsCRP, mg/l 1.2961.50 0.09e5.69 4.9368.38** 0.33e38.90
TNFa, pg/ml 2.3361.22 1.38e6.43 3.246 2.98 1.56e16.50
IL-1b, pg/ml 0.1860.08 0.09e0.34 0.3260.25* 0.09e1.00
IL- 1RA, pg/ml 216676 101e391 4906577** 194e3023
IL-6, pg/ml 1.1160.72 0.38e2.80 2.1561.67** 0.75e7.55
IL-10, pg/ml 0.8660.55 0.49e2.04 2.9864.04*** 0.49e20.86
*p<0.05; **p<0.01; ***p<0.001.
hsCRP, high-sensitivity C-reactive protein; IL-1b, interleukin 1b; IL- 1RA, interleukin 1 receptor
antagonist; IL-6, interleukin 6; IL-10, interleukin 10; TNFa, tumour necrosis factor a.
Table 4 The association of circulating cytokine levels with myocardial
maximal LGE heterogeneity at mid-ventricular level in patients with HCM
(Pearson’s correlation coefﬁcients)
LGE in CMRI
hsCRP, mg/l 0.517*
TNFa, pg/ml 0.486*
IL-1b, pg/ml 0.032
IL- 1RA, pg/ml 0.593**
IL-6, pg/ml 0.387
IL-10, pg/ml 0.038
Analysis performed using log 10 transformed values.
*p<0.05; **p<0.01.
CMRI, cardiac magnetic resonance imaging; HCM, hypertrophic cardiomyopathy; hsCRP,
high-sensitivity C-reactive protein; IL-1b, interleukin 1b; IL-1RA, interleukin 1 receptor
antagonist; IL-6, interleukin 6; IL-10, interleukin 10; LGE, late gadolinium enhancement;
TNFa, tumour necrosis factor a
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Hypertrophic cardiomyopathymyocardial samples showed NF-kB activation. NF-kB is a pivotal
intracellular mediator of inﬂammatory response, inducing the
proinﬂammatory cytokine expression.
11 NF-kB activation has
been previously implicated in cardiac dysfunction and heart
failure.
11 NF-kB activation leads to proinﬂammatory phenotype
including upregulation of TNFa, which activates inﬂammatory
cell invasion and ﬁbroblasts, resulting in perivascular ﬁbrosis
formation in the myocardium.
27 Our ﬁnding of NF-kB activa-
tion in the myocardium of patients with HCM supports the
concept that an inﬂammatory response may play an integral
part in the phenotypic expression of myocardial ﬁbrosis in
HCM.
Proinﬂammatory and anti-inﬂammatory cytokines in HCM
In this study, both proinﬂammatory and anti-inﬂammatory
cytokines were raised in patients with HCM. TNFa levels have
been reported to be increased in HCM in some,
12 14 but not in
all, previous studies.
13 IL-6 levels have been shown to be elevated
in HCM in two previous studies.
13 14 Decreased myocardial
TNFa expression has been reported after non-surgical septal
reduction in patients with obstructive HCM.
28 There are,
however, no previous studies evaluating systematically the levels
of both proinﬂammatory and anti-inﬂammatory cytokines in
patients with HCM and particularly, there are no studies
correlating levels of cytokines with LGE and other
LV characteristics in CMRI.
Clinical implications of the association of inﬂammatory response
with myocardial ﬁbrosis in HCM
CMR-derived LGE reﬂects collagenous scar formation in HCM.
29
The notion that myocardial ﬁbrosis is a potentially modiﬁable
inﬂammatory process opens interesting clinical implications in
preventing cardiovascular events in HCM, as myocardial ﬁbrosis
is a major determinant of malignant arrhythmias and end-stage
systolic heart failure in HCM and consequently, increases the
risk of cardiac death.
53 0
Strengths and limitations of the study
We demonstrated for the ﬁrst time, in a well-deﬁned genotyped
patient population with HCM, consistent signs of low-grade
myocardial inﬂammation by serological, histopathological and
immunohistochemical methods. We also showed that inﬂam-
matory response is associated with myocardial ﬁbrosis, docu-
mented by histopathological methods and LGE in CMRI. Yet,
there are some limitations to this study. First, the patient
population with HCM is of limited size. Human studies
including patients with genotype-veriﬁed diagnosis of HCM,
especially those with a single causative mutation, are, however,
few and generally small, as shown by recent studies.
31 32 Second,
it is possible that the ﬁndings of this study may not be appli-
cable to all patients with HCM with different causative muta-
tions in sarcomeric genes. However, myocardial ﬁbrosis is
a common manifestation of the HCM, LGE presenting in 80% of
cases.
1 Furthermore, according to current knowledge, no
particular clinical HCM phenotype is mutation speciﬁc.
5 Prob-
ably, the ﬁndings of this study apply to HCM caused by other
sarcomeric mutations as well, and conﬁrmation of our ﬁndings
in large genotyped patient populations is warranted. Third, in
our CMRI method, severity and not the extent of LGE was
measured. However, the method used has been regarded as
scientiﬁcally valid and shown to be associated with serum
amino-terminal propeptide of type III collagen.
16 Fourth,
cadaver myocardial specimens were used as controls and
compared with endomyocardial biopsy ﬁndings of patients with
HCM, since it is unethical to obtain endomyocardial samples
from healthy controls. Fifth, there was a variable number of
patient samples in different immunohistochemical analyses,
because the second best endomyocardial biopsy sample desig-
nated for immunohistochemical stainings was not sufﬁcient for
all microscopic slides in every patient (see online supplementary
information). Nevertheless, this study is, to our knowledge, the
ﬁrst human study to perform both endomyocardial biopsy and
CMRI in genotyped subjects with HCM.
CONCLUSIONS
In conclusion, we demonstrate that in patients with HCM
attributable to an identical disease-causing mutation in the
a-tropomyosin gene, myocardial inﬂammatory cells and
enhanced NF-kB activity are present and circulating cytokine
and hsCRP levels are increased. This inﬂammatory response is
associated with myocardial ﬁbrosis. Our ﬁndings suggest that
a low-grade inﬂammatory response plays a signiﬁcant role in the
phenotypic expression of myocardial ﬁbrosis in HCM.
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